The initiation of coverage by a major analyst like Morgan Stanley generally brings a stock into focus for investors. An Equal-Weight rating suggests that the analyst believes Novartis will perform in line with the sector or the overall market. The price target of $114 provides a benchmark for investors, but since it is not a strong buy or sell rating, the short-term impact on the stock price is likely to be neutral.